epirubicin has been researched along with Febrile Neutropenia in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Deva, S; Findlay, M; Hitchen, N; Lawrence, B; Waldron, NR | 1 |
| Nukada, T; Ohno, S; Shibata, N; Tamaki, K; Yoshinami, T | 1 |
| Bando, S; Chuma, M; Goda, M; Ishizawa, K; Kirino, Y; Morimoto, M; Nakamura, T; Sakurada, T; Takechi, K; Tangoku, A; Teraoka, K; Zamami, Y | 1 |
| Clemons, M; Dudani, S; Fergusson, D; Fernandes, R; Gyawali, B; Hutton, B; Ibrahim, MFK; Majeed, H; Mazzarello, S; Perdrizet, K; Shorr, R; Stober, C; Vandermeer, L | 1 |
| Ando, Y; Hasegawa, Y; Imai, T; Inada-Inoue, M; Kikumori, T; Mitsuma, A; Morita, S; Sawaki, M; Shibata, T; Shimokata, T; Sugishita, M | 1 |
| Chan, KK; Lee, EK; Trudeau, ME; Wong, WW | 1 |
| Brito, M; Cardoso, C; Miguel, I; Moreira, A; Sousa, M; Winckler, P | 1 |
| Denkert, C; Eiermann, W; Furlanetto, J; Lederer, B; Loibl, S; Marmé, F; Möbus, V; Nekljudova, V; Reimer, T; Reinisch, M; Schmatloch, S; Stickeler, E; Thomssen, C; Untch, M; von Minckwitz, G; Weber, K | 1 |
| Fujimori, T; Ishii, N; Kasagawa, T; Udagawa, I | 1 |
1 review(s) available for epirubicin and Febrile Neutropenia
| Article | Year |
|---|---|
Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoprevention; Cyclophosphamide; Docetaxel; Epirubicin; Febrile Neutropenia; Female; Fluorouracil; Humans; Risk Factors; Treatment Outcome | 2018 |
1 trial(s) available for epirubicin and Febrile Neutropenia
| Article | Year |
|---|---|
Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Body Surface Area; Breast Neoplasms; Capecitabine; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Febrile Neutropenia; Female; Humans; Lymphatic Metastasis; Obesity; Taxoids | 2016 |
7 other study(ies) available for epirubicin and Febrile Neutropenia
| Article | Year |
|---|---|
Real-world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first-line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Febrile Neutropenia; Gemcitabine; Humans; Middle Aged; Palliative Care; Pancreatic Neoplasms; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2023 |
Real-world data analysis of perioperative chemotherapy patterns, G-CSF use, and FN status in patients with early breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Data Analysis; Epirubicin; Febrile Neutropenia; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Polyethylene Glycols; Retrospective Studies | 2023 |
Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Japan; Middle Aged; Neoplasm Staging; Retrospective Studies | 2019 |
Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Epirubicin; Febrile Neutropenia; Female; Fluorouracil; Follow-Up Studies; Genotype; Glutathione S-Transferase pi; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Staging; Pharmacogenetics; Polymorphism, Single Nucleotide; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies | 2016 |
Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Cyclophosphamide; Docetaxel; Epirubicin; Febrile Neutropenia; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Health Care Costs; Humans; Premedication; Quality-Adjusted Life Years; Taxoids | 2015 |
Febrile neutropenia in FEC-D regimen for early stage breast cancer: is there a place for G-CSF primary prophylaxis?
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoprevention; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Febrile Neutropenia; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Agents; Hospitalization; Humans; Middle Aged; Neoplasm Staging; Portugal; Retrospective Studies; Taxoids | 2015 |
[Analysis of the Risk Factors of Febrile Neutropenia Among 72 Women Receiving FEC in Early Breast Cancer Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Febrile Neutropenia; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Retrospective Studies; Risk Factors | 2016 |